Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C?C motif chemokine receptor 6

被引:23
作者
Jin, Liyuan [1 ,2 ]
Cao, Lei [3 ]
Zhu, Yingjie [1 ,2 ]
Cao, Jiani [1 ]
Li, Xiaoyan [1 ]
Zhou, Jianxia [1 ,2 ]
Liu, Bing [4 ]
Zhao, Tongbiao [1 ,2 ]
机构
[1] Chinese Acad Sci, Inst Stem Cell & Regenerat, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
[3] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Thorac Surg, Beijing 100730, Peoples R China
[4] Acad Mil Med Sci, Affiliated Hosp, Translat Med Ctr Stem Cells, State Key Lab Prote,Ivy Translat Med Ctr 307,Lab, Beijing 100071, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
CCR6; CCL20; CAR-T; Migration; Lung cancer; ANTITUMOR-ACTIVITY; CANCER; IMMUNOTHERAPY; ANTIBODY; THERAPY; IL-7; INFILTRATION; STRATEGIES; MANAGEMENT; PROSPECTS;
D O I
10.1016/j.scib.2020.12.027
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Chimeric antigen receptor-T (CAR-T) cells have limited therapeutic efficacy against solid tumors, partially due to their limited ability to reach and invade into the neoplastic foci. By gene expression profiling interactive analysis, we identified that the C?C motif chemokine ligand (CCL) 20 is highly expressed in lung and other most incidence and/or mortality cancers such as colon, rectum, stomach, and liver cancers. Forced expression of C?C motif chemokine receptor 6 (CCR6), the biunique receptor of CCL20, results in robust trafficking of CAR-T cells toward CCL20-secreting tumor cells. In a lung cancer xenograft mouse model, CCR6-expressing CAR-T cells efficiently migrate to and infiltrate into solid tumors upon infusion, leading to effective tumor clearance and significantly prolonged survival of tumor-bearing mice. In addition, culturing CCR6-CAR-T cells with interleukin (IL)-7 and IL-15 further improved their anti-lung cancer activity. Our findings provide supporting evidence for the clinical development of chemokine receptorengineered CAR-T cells for solid tumor immunotherapy. ? 2020 Science China Press. Published by Elsevier B.V. and Science China Press. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:803 / 812
页数:10
相关论文
共 50 条
  • [1] Chimeric antigen receptor-T cell, a novel player in anti-tumor treatment
    Ni, Jieming
    Ni, Anping
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 (04) : 1143 - 1150
  • [2] Tumor Microenvironment-Responsive Nano-Immunomodulators for Enhancing Chimeric Antigen Receptor-T Cell Therapy in Lung Cancer
    Chen, Qian
    Sun, Jie
    Ling, Sisi
    Yang, Hongchao
    Li, Tuanwei
    Yang, Xiaohu
    Li, Meng
    Du, Mingming
    Zhang, Yejun
    Li, Chunyan
    Wang, Qiangbin
    ACS NANO, 2025, 19 (08) : 8212 - 8226
  • [3] Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model
    Wang, Yanan
    Wang, Jing
    Yang, Xinyi
    Yang, Jinlong
    Lu, Panpan
    Zhao, Lin
    Li, Bokang
    Pan, Hanyu
    Jiang, Zhengtao
    Shen, Xiaoting
    Liang, Zhiming
    Liang, Yue
    Zhu, Huanzhang
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [4] Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
    Craddock, John A.
    Lu, An
    Bear, Adham
    Pule, Martin
    Brenner, Malcolm K.
    Rooney, Cliona M.
    Foster, Aaron E.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 780 - 788
  • [5] The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies
    Cao, Jun-Xia
    Gao, Wei-Jian
    You, Jia
    Wu, Li-Hua
    Liu, Jin-Long
    Wang, Zheng-Xu
    CYTOTHERAPY, 2019, 21 (07) : 769 - 781
  • [6] T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
    Lesch, Stefanie
    Blumenberg, Viktoria
    Stoiber, Stefan
    Gottschlich, Adrian
    Ogonek, Justyna
    Cadilha, Bruno L.
    Dantes, Zahra
    Rataj, Felicitas
    Dorman, Klara
    Lutz, Johannes
    Karches, Clara H.
    Heise, Constanze
    Kurzay, Mathias
    Larimer, Benjamin M.
    Grassmann, Simon
    Rapp, Moritz
    Nottebrock, Alessia
    Kruger, Stephan
    Tokarew, Nicholas
    Metzger, Philipp
    Hoerth, Christine
    Benmebarek, Mohamed-Reda
    Dhoqina, Dario
    Grunmeier, Ruth
    Seifert, Matthias
    Oener, Arman
    Umut, Oyku
    Joaquina, Sandy
    Vimeux, Lene
    Tran, Thi
    Hank, Thomas
    Baba, Taisuke
    Huynh, Duc
    Megens, Remco T. A.
    Janssen, Klaus-Peter
    Jastroch, Martin
    Lamp, Daniel
    Ruehland, Svenja
    Di Pilato, Mauro
    Pruessmann, Jasper N.
    Thomas, Moritz
    Marr, Carsten
    Ormanns, Steffen
    Reischer, Anna
    Hristov, Michael
    Tartour, Eric
    Donnadieu, Emmanuel
    Rothenfusser, Simon
    Duewell, Peter
    Konig, Lars M.
    NATURE BIOMEDICAL ENGINEERING, 2021, 5 (11) : 1246 - 1260
  • [7] Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors
    Yuan, Xingxing
    Sun, Zujun
    Yuan, Qingyun
    Hou, Weihua
    Liang, Qiaoyan
    Wang, Yuxiong
    Mo, Wei
    Wang, Huijie
    Yu, Min
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 34 - 51
  • [8] c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer
    Kang, Chung Hyo
    Kim, Yeongrin
    Lee, Da Yeon
    Choi, Sang Un
    Lee, Heung Kyoung
    Park, Chi Hoon
    CANCERS, 2021, 13 (22)
  • [9] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
    Rupp, Levi J.
    Schumann, Kathrin
    Roybal, Kole T.
    Gate, Rachel E.
    Ye, Chun J.
    Lim, Wendell A.
    Marson, Alexander
    SCIENTIFIC REPORTS, 2017, 7
  • [10] Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy
    Rashidijahanabad, Zahra
    Huang, Xuefei
    SEMINARS IN IMMUNOLOGY, 2020, 47